CL2020002252A1 - Formulación oftálmica. - Google Patents

Formulación oftálmica.

Info

Publication number
CL2020002252A1
CL2020002252A1 CL2020002252A CL2020002252A CL2020002252A1 CL 2020002252 A1 CL2020002252 A1 CL 2020002252A1 CL 2020002252 A CL2020002252 A CL 2020002252A CL 2020002252 A CL2020002252 A CL 2020002252A CL 2020002252 A1 CL2020002252 A1 CL 2020002252A1
Authority
CL
Chile
Prior art keywords
ophthalmic formulation
ophthalmic
active compound
pharmaceutically active
aqueous solubility
Prior art date
Application number
CL2020002252A
Other languages
English (en)
Inventor
Stefan Sperl
Franz Obermayr
Original Assignee
Panoptes Pharma Ges M B H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptes Pharma Ges M B H filed Critical Panoptes Pharma Ges M B H
Publication of CL2020002252A1 publication Critical patent/CL2020002252A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una composición oftálmica que comprende un compuesto farmacéuticamente activo oftálmico y albúmina, en la que la solubilidad acuosa del compuesto farmacéuticamente activo aumenta en al menos un 10 % en presencia de albúmina en comparación con la solubilidad acuosa del mismo.
CL2020002252A 2018-03-09 2020-08-31 Formulación oftálmica. CL2020002252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18160981 2018-03-09

Publications (1)

Publication Number Publication Date
CL2020002252A1 true CL2020002252A1 (es) 2021-04-30

Family

ID=61622364

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002252A CL2020002252A1 (es) 2018-03-09 2020-08-31 Formulación oftálmica.

Country Status (15)

Country Link
US (1) US12472263B2 (es)
EP (1) EP3761960B1 (es)
JP (1) JP7081850B2 (es)
KR (1) KR102496934B1 (es)
CN (1) CN111163757B (es)
AU (1) AU2019232153B2 (es)
BR (1) BR112020017988A2 (es)
CA (1) CA3092234A1 (es)
CL (1) CL2020002252A1 (es)
ES (1) ES2972099T3 (es)
IL (1) IL276918B2 (es)
MX (1) MX2020009235A (es)
PL (1) PL3761960T3 (es)
WO (1) WO2019170848A1 (es)
ZA (1) ZA202005233B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6629840B2 (ja) 2014-05-08 2020-01-15 パノプテス・ファーマ・ゲーエムベーハー 眼の疾患および障害を処置するための化合物
IT201900022881A1 (it) * 2019-12-03 2021-06-03 Ntc Srl Budesonide per uso oftalmico in un metodo di trattamento dell’occhio
CN112933075A (zh) * 2019-12-11 2021-06-11 刘力 局部给药的葛根相关药物组合物
KR20240007144A (ko) 2021-04-09 2024-01-16 이뮤닉 아게 중수소화 dhodh 억제제
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물
CN114577957A (zh) * 2021-12-21 2022-06-03 益诺思生物技术南通有限公司 一种虹膜中伏立康唑药物的检测方法
UY40087A (es) 2021-12-23 2023-06-30 Immunic Ag Inhibidores de DHODH que contienen un bioisóstero de ácido carboxílico.
EP4201398A1 (en) * 2021-12-24 2023-06-28 Isoxa S.r.l. Isocyclosporin a for topical treatment of ocular diseases
WO2023168176A1 (en) * 2022-03-01 2023-09-07 Kiora Pharmaceuticals Gmbh Salts of a dihydroorotate dehydrogenase (dhod) inhibitor
UY40805A (es) 2023-06-28 2025-01-15 Immunic Ag Inhibidores de dhodh heteroaromáticos
CN116687840B (zh) * 2023-08-03 2023-10-20 四川省医学科学院·四川省人民医院 一种用于治疗眼部病状的凝胶制剂及其制备方法
CN118557746A (zh) * 2024-05-30 2024-08-30 四川大学 一种夫西地酸白蛋白复合物及其制备方法与应用
WO2026074007A1 (en) 2024-10-02 2026-04-09 Immunic Ag Nurr1 agonists with replacement of the carboxylic acid or carboxamide moiety for use in the treatment of neurodegenerative diseases
CN120789284A (zh) * 2025-09-18 2025-10-17 通化安睿特生物制药股份有限公司 一种包载环孢菌素a的白蛋白结合型药物及制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61103836A (ja) * 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
DD297328A5 (de) 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
JPH0834320A (ja) * 1994-07-25 1996-02-06 Senshiyaki Service:Kk 車両用の温風乾燥機
DE69730476T2 (de) 1996-04-19 2005-11-17 Tsubota, Kazuo, Funabashi Albumin als aktiver Bestandteil zur Behandlung von Bindehaut- und Hornhautverletzungen und von trockenen Augen
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
AU2003301347A1 (en) 2002-10-17 2004-05-04 Control Delivery Systems, Inc. Methods for monitoring treatment of disease
WO2004056746A1 (en) 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
PT1578741E (pt) 2002-12-23 2011-10-17 4Sc Ag Compostos aromáticos como agentes antiinflamatórios, imunoreguladores e antiproliferativos
WO2004056747A1 (en) 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
US7365094B2 (en) 2002-12-23 2008-04-29 4Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
JP4051398B2 (ja) 2004-03-11 2008-02-20 アクテリオン ファマシューティカルズ リミテッド テトラヒドロピリドインドール誘導体
JP2006089485A (ja) 2004-08-24 2006-04-06 Santen Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
US20070082841A1 (en) 2005-09-27 2007-04-12 Aciont, Inc. Ocular administration of immunosuppressive agents
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
JP2009270356A (ja) 2008-05-08 2009-11-19 Yoshinobu Hayashi アスベスト含有被覆層剥ぎ取り物の処理方法
TWI530286B (zh) 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑
US20110021465A1 (en) 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
RU2016144238A (ru) 2014-04-11 2018-05-11 Паноптес Фарма Гмбх Противовоспалительные средства в качестве вирусостатических соединений
JP6629840B2 (ja) * 2014-05-08 2020-01-15 パノプテス・ファーマ・ゲーエムベーハー 眼の疾患および障害を処置するための化合物
MX2018008169A (es) 2015-12-30 2019-02-20 Agios Pharmaceuticals Inc Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
KR20240007144A (ko) 2021-04-09 2024-01-16 이뮤닉 아게 중수소화 dhodh 억제제
WO2023168176A1 (en) 2022-03-01 2023-09-07 Kiora Pharmaceuticals Gmbh Salts of a dihydroorotate dehydrogenase (dhod) inhibitor
EP4489745A4 (en) 2022-03-09 2025-10-15 Kiora Pharmaceuticals Gmbh POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR

Also Published As

Publication number Publication date
CA3092234A1 (en) 2019-09-12
IL276918B1 (en) 2024-06-01
WO2019170848A1 (en) 2019-09-12
NZ767268A (en) 2025-03-28
MX2020009235A (es) 2023-01-16
EP3761960A1 (en) 2021-01-13
ES2972099T3 (es) 2024-06-11
EP3761960C0 (en) 2023-11-22
US12472263B2 (en) 2025-11-18
JP2021515777A (ja) 2021-06-24
AU2019232153A1 (en) 2020-09-10
IL276918A (en) 2020-10-29
ZA202005233B (en) 2022-02-23
AU2019232153B2 (en) 2023-07-13
KR20200130280A (ko) 2020-11-18
PL3761960T3 (pl) 2024-04-15
KR102496934B1 (ko) 2023-02-06
CN111163757B (zh) 2022-04-19
JP7081850B2 (ja) 2022-06-07
CN111163757A (zh) 2020-05-15
EP3761960B1 (en) 2023-11-22
IL276918B2 (en) 2024-10-01
BR112020017988A2 (pt) 2020-12-22
US20210052737A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX387604B (es) Formulaciones cannabinoides estables.
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
EA201690810A1 (ru) Мягкие пастилки, содержащие экстракт куркумы
MX2018000285A (es) Composicion para desobstruir la nariz congestionada que tiene actividad antiviral.
MX2022008479A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX369474B (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
MX2019002396A (es) Composiciones oftalmicas.
PH12019502676A1 (en) Moisturizing topical preparation
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
CO2018007810A2 (es) Formulación líquida estable de gonadotropina
MX2017016774A (es) Agente terapeutico para la fibrosis.
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX376118B (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
MX382396B (es) Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales.
EA201992296A1 (ru) Производные хиноксалина и пиридопиразина в качестве ингибиторов pi3k-бета
MX388699B (es) Formas cristalinas de cabotegravir de sodio
BR112017014295A2 (pt) composição farmacêutica.
CO2020002287A2 (es) Composiciones farmacéuticas
MX383146B (es) Composición farmacéutica de disgregación rápida.
CO2017000354A2 (es) Desmopresina estabilizada